Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
Breast Cancer
DRUG: Bevacizumab, Abraxane
To determine progression-free survival among women receiving bevacizumab + ABI-007 given as second-line combination therapy for hormone receptive negative, Her-2 negative metastatic breast cancer., Study Completion
To determine the overall response rate to bevacizumab + ABI-007 in this study population., Study completion|To determine the toxicity of bevacizumab + ABI-007 in this study population., Study completion
The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.